Canada covid-19 pandemic Government patient Canada

Canadian Government invests $175.6m in AbCellera’s Covid-19 response

Reading now: 882
www.pharmaceutical-technology.com

At the beginning of May, the Government of Canada committed $175.6m in funding to Vancouver-based AbCellera Biologics, a biotech company focused on developing antibody-based drugs.

The funding came through the Ministry of Innovation, Science and Economic Development’s Strategic Innovation Fund (SIF). This support for AbCellera’s work comes as part of the government’s Plan to Mobilise Science against Covid-19, which aims to support national projects that will contribute to the global race against Covid-19, as well as improve the country’s resilience against future pandemics.

AbCellera is leveraging its proprietary antibody drug discovery technology to help identify antibodies from blood samples of recovered Covid-19 patients for drug

Read more on pharmaceutical-technology.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA